The connection between increased HO activity and hyperbilirubinemia has also been clinically confirmed, since Sn-mesoporphyrin-IX, a well-known HO inhibitor, reduces BR plasma levels in babies affected by hemolytic and Crigler-Najjar type I diseases [148,149]. This evidence concerns the gene HMOX1 and Hyperbilirubinemia.